Par Drugs & Chemicals Ltd (PAR) — shareholding pattern, promoter holding, financials and share price
About Par Drugs & Chemicals Ltd (PAR)
Par Drugs & Chemicals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PAR and on the BSE under scrip code 535341. Its ISIN is INE04LG01015.
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals [1]
Par Drugs and Chemicals Limited manufactures Active Pharma Ingredients (APIs) and fine chemicals for both domestic and international markets, operating two facilities in Gujarat, India.
The company focuses on a diversified portfolio with 12 APIs and 6 fine chemicals, expanding its market reach to approximately 16 countries.
Listed peers in Pharmaceuticals: Pharmaids Pharmaceuticals Ltd, Krebs Biochemicals & Industries Ltd, Sotac Pharmaceuticals Ltd, Denis Chem Lab Ltd, Vaishali Pharma Ltd, Mercury Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹89.58 a share on 10 Jul 2026, Par Drugs & Chemicals Ltd (PAR) was valued at a price-to-earnings ratio of 8.41x against an industry P/E of 36.41x and a price-to-book of 1.11x on a book value of ₹80.44 per share as of Mar 2025. Solomo computes return on equity of 13.25% and return on capital employed of 17.6% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 8.41x
- Industry P/E
- 36.41x
- P/B
- 1.11x
- EPS (TTM)
- ₹10.65
- Book value / share
- ₹80.44
- ROE
- 13.25%
- ROCE
- 17.6%
- ROA
- 10.98%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 20.39%
- 52-week range
- ₹78.05 – ₹122.43
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Par Drugs & Chemicals Ltd (PAR) reported revenue of ₹104 crore, net profit of ₹13 crore and earnings per share of ₹10.65. That compares with revenue of ₹101 crore and net profit of ₹13 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹19.61 crore and net profit ₹0.85 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 75 | 96 | 96 | 101 | 104 |
| Net profit (₹ cr) | 9 | 11 | 14 | 13 | 13 |
| EPS (₹) | 7.49 | 9.21 | 11.78 | 10.86 | 10.65 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 15.22% | 10.15% | 5.57% |
| Profit growth | 22.90% | 13.18% | -7.86% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.41% of Par Drugs & Chemicals Ltd (PAR) (unchanged from the previous quarter). Market capitalisation was ₹110 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2019.
Largest disclosed public shareholders in Jun 2026: Econo Trading And Investment Private Limited 1.8%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.41% | - | - | - | - |
| Mar 2026 | 73.41% | - | - | - | - |
| Dec 2025 | 73.41% | - | - | - | - |
| Sep 2025 | 73.37% | - | - | - | - |
| Jun 2025 | 73.37% | - | - | - | - |
| Mar 2025 | 73.37% | - | - | - | - |
| Dec 2024 | 73.37% | - | - | - | - |
| Sep 2024 | 73.37% | - | - | - | - |